VECTION TECHNOLOGIES

For personal use only

11 March 2021 | Australia

ASX RELEASE

LAUNCH OF HEALTHCARE & PHARMA SOLUTIONS VERTICAL

FIRST MILESTONE IN THE 2021 VERTICALIZATION STRATEGY

Real-time software company Vection Technologies Ltd (**ASX:VR1**) (**Vection Technologies**, **Vection** or the **Company**) is pleased to announce the acceleration of its Verticalization growth strategy with the launch of its Healthcare & Pharma Solutions division.

The Company will be joining forces with a strong team of professionals led by Dr Carlo Centemeri, a leading healthcare and pharma executive with senior experience in BASF, Knoll Pharmaceuticals, Abbott Laboratories, Bristol-Myers Squibb and AstraZeneca. Furthermore, he led as Managing Director the Education and Simulation Center of the Gemelli University Hospital in Rome and Elsevier Pharma & Health Industries as Executive Director. He currently serves as Medical Science Senior Advisor to the Italian Ministry of Health and as Strategy and Development Senior Managing Partner at the Giovanni Lorenzini Medical Foundation of Milan and New York. Carlo is an Adjunct Professor of Pharmacology at Padua, Milan and Rome Universities.

Highlights:

- **Vection strongly accelerates its international growth strategy with the launch of its Healthcare & Pharma Solutions Division**
- **Vection joins forces with highly experienced team with former roles in BASF, Knoll Pharmaceuticals, Abbott Laboratories, Bristol-Myers Squibb, AstraZeneca, Novartis, Boehringer Ingelheim and Dompé Farmaceutici**
- **Strong commitment by the executive team with joint division ownership and strong opportunities pipeline anticipated to come to fruition from April 2021**
- **Strong ability to attract senior industry-specific executives key for the Company's growth acceleration**
- **Expansion of Vection's footprint in the healthcare, pharmaceutical, biotechnological, medical devices and nutraceutical market segments leveraging its existing core technology stack**
- **Strategic division for continued growth during the current pandemic aligned with the digital transformation trend in healthcare**
- **First milestone in the 2021 Verticalization strategy achieved**
- **A brief presentation of the Healthcare & Pharma Solutions division is appended to this announcement**

3D
VIRTUAL REALITY
AUGMENTED REALITY
INDUSTRIAL IoT
CAD

Asia Pacific
Address: 642 Newcastle Street, Leederville WA 6007
Phone: +618 6380 2555

Europe
Address: Via Isonzo 61
40033 Casalecchio di Reno (BO), Italy

North America
Address: 785 Market Street, #600
San Francisco CA 94103
USA

Media Enquiries
AUpress@vection.com.au
EUpress@vection.com.au

ASX

VECTION TECHNOLOGIES

Vection Healthcare & Pharma Solutions - Overview:

During the first half of the fiscal year, Vection strongly advanced its commercial initiatives with Dr Centemeri to lay the necessary groundwork to achieve the optimum global market penetration for the second half growth. Today, following extensive negotiations, the Company has secured the strong commitment of Dr Centemeri through the incorporation of a joint venture company controlled by Vection at 60%. (**Vection Healthcare & Pharma Solutions**)

Vection Healthcare & Pharma Solutions - Rationale:

The shareholding structure of Vection Healthcare & Pharma Solutions ensures a strong commitment on global growth by the executive team of this vertical, in addition to delivering a significant pipeline of opportunities anticipated to come to fruition commencing from the month of April 2021.

Vection Healthcare & Pharma Solutions - Executive Team:

Through the incorporation of Vection Healthcare & Pharma Solutions, the Company has secured a team of 6 professionals with previous experience in strategic companies including BASF, Knoll Pharmaceuticals, Abbott Laboratories, Bristol-Myers Squibb, AstraZeneca, Novartis, Boehringer Ingelheim and Dompé Farmaceutici.

Vection Healthcare & Pharma Solutions - Strategy:

Vection Healthcare & Pharma Solutions represents a strong acceleration in the Company's Verticalization strategy, a tactical approach that seeks to significantly expand Vection's footprint in the healthcare, pharmaceutical, biotechnological, medical devices and nutraceutical market segments.

Vection Healthcare & Pharma Solutions seeks to lead the Company into medical-technical-scientific education & communication by becoming the reference solution provider for the public and private sector operating in the life-science world. It will develop unique and highly innovative educational and communication models in the the healthcare, pharmaceutical, biotechnological, medical devices, and nutraceutical market segments through the vertical integration of Vection's current core technology stack.

The proposed training and communication approach adopts, among others, advanced behavioural simulation techniques including Virtual and Augmented Reality technologies, that have demonstrated essential benefits across diverse market segments for increased quality of teaching and learning, to ensure the effective education of Health Care Professionals (**HCPs**) and personnel.

Leveraging the overarching organizational, structural and methodological renewal trend of the entire healthcare industry, Vection Healthcare & Pharma Solutions seeks to take advantage of all the opportunities that digital education offers. Thus, the development of medical practices, the improvement of soft skills relationships with patients and caregivers and the advancement of business acumen between all health stakeholders is today one of the crucial elements of the digital transformation in the health sciences where Vection seeks to operate.

3D

VIRTUAL REALITY

AUGMENTED REALITY

INDUSTRIAL IoT

CAD

Asia Pacific
Address: 642 Newcastle Street, Leederville WA 6007
Phone: +618 6380 2555

Europe
Address: Via Isonzo 61
40033 Casalecchio di Reno (BO), Italy

North America
Address: 785 Market Street, #600
San Francisco CA 94103
USA

Media Enquiries
AUpress@vection.com.au
EUpress@vection.com.au

ASX

A brief presentation of the Healthcare & Pharma Solutions division is appended to this announcement.

Gianmarco Biagi, Managing Director of Vection Technologies, commented:

"The Healthcare & Pharma Solutions division represents a strong acceleration and the achievement of the first milestone in the Company's overarching Verticalization growth strategy in a key market segment.

Following extensive groundwork and negotiations by the executive team during the first half of the fiscal year, we have now secured the full commitment of Dr Centemeri and his team, leading market experts with unrivalled senior experience and network in this vertical - a strong endorsement of the Company's ability to attract the best talent key for the Company's growth.

The Company's management anticipates to significantly progress the next milestones in its Verticalization growth strategy in the short-term, ensuring unrivalled acceleration in the industry."

Carlo Centemeri, CEO of Vection Healthcare, commented:

"The global COVID-19 pandemic has forced healthcare systems to radically change their operational structure. In this context, digital transformation is paramount and critical.

Our mission is to rapidly gain market share in healthcare education, communication, digital networking, big data and operational solutions through the proposition of outstanding Innovative Technological Methodologies. Our ambition is to become a market reference point as leaders in the behavioural simulation immersive training field, leveraging Vection's virtual reality, augmented reality, motion capture, morphing and avatar-based solutions."

Vection Technologies Investor Relations Contact Details

Gianmarco Biagi - Managing Director (Europe Based)
Email: gianmarco.biagi@vection.com.au
Phone: +39 051 0142248

Gianmarco Orgnoni - Director and COO (Australia Based)
Email: gianmarco.orgnoni@vection.com.au
Phone: +61 8 6380 2555

ENDS

3D
VIRTUAL REALITY
AUGMENTED REALITY
INDUSTRIAL IoT
CAD

About Vection Technologies:

Vection Technologies Ltd (ASX:VR1) is a multinational software company that focuses on real-time technologies for industrial companies' digital transformation.
Through a combination of our 3D, Virtual Reality, Augmented Reality, Industrial IoT and CAD solutions, Vection Technologies helps companies and organisations to innovate, collaborate and create value.
For more information please visit the Company's websites:
vection.com.au
mindeskvr.com

About the Leading Strategy:

Following the completion of the first two phases of its overarching strategy – namely, Rebuilding (2017-2018) and Transforming (2019-2020) – resulting in the development of its solid core technology stack, the Company has now progressed to the Leading Strategy phase (2021-2023), with "Verticalization" being its first foundational step. The Verticalization approach seeks to significantly expand Vection's footprint in companies' application landscapes, segmenting industrial markets while capturing new business opportunities, protecting market positions and averting competitive threats. As part of this approach, Vection wants to develop highly verticalized extensions to its core technology stack aimed at anchoring its solutions in clients' core processes. The Company will follow a Build / Acquire / Partner strategy where, in each vertical industry, it will analyse the benefits of internally building functionality, working with a partner or acquiring companies.

ASX release authorised by the Board of Directors of Vection Technologies Ltd.

3D
VIRTUAL REALITY
AUGMENTED REALITY
INDUSTRIAL IoT
CAD

Asia Pacific
Address: 642 Newcastle Street,
Leederville WA 6007
Phone: +618 6380 2555

Europe
Address: Via Isonzo 61
40033 Casalecchio di Reno (BO),
Italy

North America
Address: 785 Market Street, #600
San Francisco CA 94103
USA

Media Enquiries
AUpress@vection.com.au
EUpress@vection.com.au

VECTION TECHNOLOGIES

VECTION HEALTH CARE & PHARMA

(ASX:VR1)

MARCH 11, 2021

DISCLAIMER

This presentation has been prepared by Vection Technologies Limited (ACN 614 814 041) (Vection Technologies or the Company) and is for information purposes only. It does not constitute financial product or investment advice or a recommendation to acquire Vection Technologies shares and has been prepared without taking into account the objectives, financial situation or needs of individuals. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs and seek legal and taxation advice appropriate to their jurisdiction. Vection Technologies is not licensed to provide financial product advice in respect of Vection Technologies shares.

Vection, Vection Technologies, FrameS, Mindesk, and their respective logos, are trademarks or registered trademarks of Vection Technologies, or its subsidiaries. All other registered or unregistered trademarks mentioned in this presentation are the property of their respective owners, and no trademark rights to the same are claimed.

Financial Data - All dollar values are in AUD dollars (AUD or $) unless otherwise presented.

Future performance - Forward looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Forward looking statements including projections, guidance on future earnings and estimates are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. An investment in Vection Technologies shares is subject to investment and other known and unknown risks, some of which are beyond the control of Vection Technologies. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Vection Technologies employees, its directors, employees or agents, nor any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of the information contained in this presentation. In particular, no representation or warranty, express or implied is given as to the accuracy, completeness or correctness, likelihood of achievement or reasonableness of any forecasts, prospects or returns contained in this Presentation nor is any obligation assumed to update such information. Such forecasts, prospects or returns are by their nature subject to significant uncertainties and contingencies. Before making an investment decision, you should consider, with or without the assistance of a financial adviser, whether an investment is appropriate in light of your particular investment needs, objectives and financial circumstances.

INTRODUCTION

- ## Healthcare

The pandemic is rapidly driving organizational change and prompting health IT leaders to consider future needs and opportunities.

healthtechmagazine.net, Dec20

The pandemic has also brought us to a unique moment where we are learning at scale that data science and digital technology can improve human health in powerful ways. This is digital healthcare's moment, and there are clear steps the international community can take to meet it.

Davos Agenda, Jan21

- ## Pharma

COVID-19 and the digital pharma marketing revolution
The global outbreak of COVID-19 has forced businesses to radically change their way of working. Healthcare companies have been in the vanguard of this change, with an enormous rise in the use of telehealth and all forms of digital communication and education.
...Once the global emergency ends, this trend will continue...

pharmaforum.com, Jan21



VECTION TECHNOLOGIES

THE OPPORTUNITY IS NOW

VISION & MISSION

VISION

To provide effective proven Health Solutions

MISSION

To provide outstanding Health Solutions through Innovation and Technology, gaining a growing market share in the field of health education and operation services and being recognised as a leader in the simulation immersive training field.

Education & Training

- Immersive experiential training and educational tools
- Advanced immersive and highly engaging webinars
- Coaching/training for sales and medical field forces
- Strong access to the healthcare sector

Communication
(advertising & promotion)

Evolved, immersive and engaging platforms for healthcare professionals and public communications

Hospital and out-patient software development & Telemedicine

Vection's VR & AR innovative solutions for hospitals and remote-controlled devices and tools

More

Bespoke projects and ad-hoc solutions leveraging a strong industry network

STRATEGY

STRATEGY
for Vection Health & Pharma
with greater added value

April - July 2021
Intelligence activities with CEO/GMs in the Healthcare & Pharma industry
First client sales

May - July 2021
Acceleration of commercial activities

Sep - Nov 2021
Projects co-development with key clients and opinion leaders/supporters

Dec - Jan 2021
Strong contracts and orders with clients

2022
Full roll-out of solutions

PEOPLE

VECTION TECHNOLOGIES

CEO & Managing Director
(Dr Carlo Centemeri)

CME & Communication

Chief Scientific Officer

Education & Integration Solutions Senior Manager

Sales & Mktg Solutions Director

Business Development Manager - Pharma Industries

Business Development Manager -Hospitals

Team with competency and senior experiences in the Pharma and Healthcare field

FLEXIBILITY

Flexible team with strong skills and industry specific expertise.

Wealth of experience: Dompé, Boehringer Ingelheim, AstraZeneca, BASF We create chemistry, NOVARTIS

VERTICAL OBJECTIVES

VECTION TECHNOLOGIES

CORE TECHNOLOGIES

MINDESK | FRAMES | TRAINER CREATOR

Healthcare & Pharma

LUISS CGM CompuGroup Medical

Key Vertical

- Strong growth segment
- Internally build functionality
- Addition of expertise with launch of new division

ACE & Real Estate

Zaha Hadid
Heatherwick studio

Key Vertical

- Strong growth segment
- External opportunities to expand competencies for value added industry verticalisation

Comunication & Media

Haier VOLVO

Key Vertical

- Strong growth segment
- Internally build functionality
- Addition of expertise with launch of new division or via external opportunities

Fashion & Retails

GIORGIO ARMANI GUCCI

Key Vertical

- Strong growth segment
- Internally build functionality
- Addition of expertise with launch of new division

Others

Key Vertical

- dentification of technologies key for vertically integrated solutions Including: cyber security, IoT, CAD, BIM and more
- Identification of consulting arm for value added creation

IDENTIFIED VERTICALS

VECTION TECHNOLOGIES

Investor Relations Contact Details

Gianmarco Biagi - Managing Director (Europe Based)
Email: gianmarco.biagi@vection.com.au
Phone: +39 051 0142248

Gianmarco Orgnoni - Director and COO (Australia Based)
Email: gianmarco.orgnoni@vection.com.au
Phone: +61 8 6380 2555

Corporate Headquarters

642 Newcastle Street,
Leederville WA 6007

Europe Headquarters

Via Isonzo 61,
40033 Casalecchio di Reno (BO), Italy

Europe R&D

Via Volga c/o Fiera del levante,
70132 Bari (BA), Italy

North America Headquarters

785 Market Street, #600
San Francisco CA 94103, USA

India Operations

903, Samedh Complex,
Panchvati Cross Road,
C.G Road, Ahmedabad – 380009 Gujarat, India

vection.com.au

mindeskvr.com